Dr. Greg Vigna Study reveals Depo-Provera exposure causes distinct genetic mutations in meningiomas, with increased risk of multiple tumo ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

A study published in Nature Genetics reveals new insights into how medulloblastoma, the most common malignant brain tumor of ...

An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in a Phase III STEER study (NCT05089656) ...

Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully ...

Enliven's initial phase 1 data for ELVN-001 in CML shows promising tolerability and activity in heavily pretreated patients. But read why ELVN stock is a Sell.

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

Using ancient DNA, researchers identified migration patterns in Europe during the first millennium AD, linking genetic ...

AI presents an opportunity to reshape the global regulatory landscape, enabling precise risk assessment and data-driven ...

Discover CDC findings on COVID-19 variants and vaccine protection, revealing key insights into emerging strains and public ...